Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Baird sold ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. On ...

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...